Biogen Builds Out Parkinson's Pipeline With Denali Deal

 
• By Jessica Merrill

Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.

PARTNERS word made with building blocks
Biogen and Denali are teaming up in Parkinson's disease • Source: Shutterstock

More from Deals

More from Business